Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Initial Dose of Zomig Offers Relief For Most Migraine Attacks SAN FRANCISCO, CA -- June 30, 1998 -- One dose of Zeneca Pharmaceuticals’ Zomig (TM) (zolmitriptan) 2.5 or 5.0 mg, a selective serotonin agonist for acute migraine, successfully treats eight out of 10 migraine attacks at two hours, according to results of an international, multicentre, open-label study presented at the American Association for the Study of Headache meeting. These new results from this study of 49,000 migraine attacks, show that for most migraine sufferers, Zomig may break the cycle of migraine. "Not only can migraine be completely debilitating during an attack, but the anxiety of the next attack also may reduce a patient's quality of life," said Dr. Alexander Mauskop of the New York Headache Center and lead author on data presented at the meeting. "For those patients treating up to 25 attacks over a six-month period, a single dose of Zomig 2.5 mg demonstrated response rates greater than 80 percent ." Results from this study show that when patients taking a second dose for persistent headache are included, a successful headache response (two hours after final dose) was seen in 95 percent of the attacks. Zomig 2.5- and 5.0-mg tablets were cleared for marketing by the U.S. Food and Drug Administration in November 1997 for treatment of acute migraine with or without aura in adults. Zomig was made available by prescription in pharmacies nation-wide in January of 1998. More information on: Zomig, Zeneca Pharmaceuticals E-mail this page to a friend or colleague! To print, use this version